MPR YIR RA 2019

Eticovo, a Biosimilar to Enbrel, Gets FDA Approval

The Food and Drug Administration (FDA) has approved Eticovo (etanercept-ykro; Samsung Bioepis), a biosimilar to Enbrel (etanercept; Amgen). Eticovo is a tumor necrosis factor (TNF) blocker. Its biosimilarity has been demonstrated for the following indications: Rheumatoid arthritis (RA): reducing signs/symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in…